A Review of the Methods, Interpretation, and Limitations of the Urine Drug Screen E. Claire Markway, PharmD; Stephanie N. Baker, PharmD, BCPS T oxicology screens are commonly used in various health care settings. These screening tests can be broadly defi ned as an examination of a biological specimen to detect the presence of a specifi c chemical substance or its metabolites.
1,2 Specimens such as urine, hair, saliva, sweat, and blood may be tested. This article discusses the urine toxicology screen or urine drug screen (UDS), as this is the most frequently used in clinical practice.
METHODS OF TOXICOLOGY SCREENING Biological Specimen
The source of the biological specimen used in toxicology screens affects certain characteristics of these tests, including the period of detection. This period can be defi ned as the duration of time elapsed from when a substance was last used (assuming typical use) that one could expect to still obtain a positive qualitative result. 2, 3 In general, hair specimens have an increased period of detection compared to other biological specimens, with some substances being detected up to 90 days after last use. [2] [3] [4] Saliva testing is considered to have the shortest period of detection, with most substances only being recognized if used within the past 24 to 48 hours. [2] [3] [4] However, patients who extensively use substances at higher quantities or frequencies than typical use may have prolonged periods of detection regardless of the biological specimen. 2 Providers must also account for the specifi c substance being screened, because certain characteristics like pharmacokinetic parameters may alter the usual period of detection. Overall, the UDS is the most frequently used method based on convenience, cost, and accessibility. 2, 3 The basic differences in the periods of detection in the UDS based on the substance being screened are summarized in Table 1 .
Clinical Use
Urine drug screens can be used for various reasons. In certain clinical scenarios, a toxicology screen may assist practitioners in narrowing their initial differential diagnosis list. Common reasons that toxicology screens are ordered include emergency situations such as traumas, seizures, or signifi cant altered mental status; concern for intentional or accidental overdose; monitoring drug dependency; and screening for medical or legal purposes. 2, 6, 8 Prior to ordering these screening tests, it is important to consider their purpose.
A 2009 review article analyzed 1405 patients who presented to the emergency Abstract: Toxicology screens are used to detect the presence of prescription, nonprescription, or illicit substances. These tests are used in emergency situations to detect intentional or accidental overdose, to monitor drug dependency, and to screen for medical or legal purposes. An initial immunoassay reports qualitative results based on established cut-off concentrations. As a screening test, the initial immunoassay is less sensitive and therefore must be interpreted in the context of confounding variables such as the testing method, the substance being screened, and patient-specifi c characteristics. Either gas chromatography or high-performance liquid chromatography can be used to confi rm positive results.
■ pharmacology update department to determine how a UDS affects patient management in the emergency department. 8 The conclusion of the reviewers was that UDSs in the emergency department did not signifi cantly impact patient management during their stay. 8 Therefore, the authors recommended against routine UDSs in this setting. 8 Regarding the UDS as a screen for opiate use, the American Pain Society refers to the UDS as a potential method to monitor chronic opiate use in noncancer patients. However, they also note the limitations of most of the evidence supporting the accuracy of UDSs in this setting. In 2010, a systematic review specifi cally attempted to address the question of whether routine UDSs deterred abuse of opiates. 10 Reviewers found 11 observational studies that met inclusion criteria and, based on these trials, concluded there was a modest, nonstatistically signifi cant decrease in opiate abuse with routine UDSs. 10 Four of these studies compared specifi c monitoring treatment agreements, some of which included routine UDSs, to a control group and found the incidence of opiate misuse had an absolute relative risk reduction from 7% to 23% with the monitored group. 10 It is important for providers to recognize the benefi ts and limitations of the UDS to use it appropriately in clinical practice. Providers should understand that the UDS is a screening test and should not be considered diagnostic. 
Screening Techniques
Clinical laboratories may use various testing methods, but the most common techniques include the spot test, spectrochemical test, immunoassay, and chromatographic testing. Spot tests are simple tests that result in a color change due to a chemical reaction. These tests, although rapid, have for the most part fallen out of favor due to the subjective interpretation of the change in color resulting in decreased sensitivity.
Spectrochemical testing methods like spot tests also analyze a chemical reaction. A spectrophotometer measures the changes in light absorbance throughout the course of the chemical reaction in rate spectrophotometry. This serves to quantitatively measure light absorption at different wavelengths to identify various substances. The issue with this screening method is the low sensitivity, in that other substances that either alter the chemical reaction or alter light absorption may confound the result. Based on the limitations of both the spot and spectrochemical tests, the immunoassay and chromatographic testing methods are typically the most used.
1,2
The UDS, like most toxicology screening methods, is part of a 2-step process that incorporates the immunoassay and the chromatographic testing method. The fi rst step is the immunoassay, which works by either competitive or noncompetitive binding. Urine drug screens typically work competitively, which means the drug substance itself displaces some previously labeled substance originally on the antibody.
The most frequently used UDSs work by homogenous immunoassay, which, rather than detecting for the presence of the unbound labeled substance, compares the concentration of the labeled free vs the concentration of the labeled attached substance. Types of homogeneous immunoassays include enzyme-multiplied immunoassay technique, fl uorescence polarization immunoassay, and radioimmunoassay. 1, 2 Immunoassays are sensitive, fairly inexpensive tests and are relatively easy to perform because they are easily collected and automated. 2, 3, 6 Poor sensitivity is a concern with the fi rst step of the UDS process, so a confi rmatory test is recommended for immunoassay positive results. 2 Confi rmatory tests are frequently done via the second step, gas chromatography-mass spectrometry or high-performance liquid chromatography. Chromatography tests work by separation of substances into a mobile and a stationary phase. The amount of time in the mobile phase correlates to a specifi c length that is reproducible under specifi c conditions, which are mimicked in the UDS. These testing methods are more cumbersome than the other methods; however, they are the most sensitive and specifi c tests to help exclude false positive results. Providers should know their clinical laboratory protocols because depending on the policy, confi rmatory tests may or may not be automatic for positive results. If these tests are not routine, providers may have to specifi cally request a confi rmatory test.

INTERPRETATION OF RESULTS
Qualitative Reporting
The fi rst thing to consider when interpreting UDS results is what the qualitative result from the immunoassay really indicates. Positive and negative results are differentiated based on established cut-off values. This means that substances above a certain concentration in the UDS correlate with a positive result, and if the concentration is less than the established value, a negative result is reported. Therefore, a negative result for a particular substance does not necessarily correlate to it not being present, but rather the ■ pharmacology update concentration present is less than the established cut-off value. Furthermore, these values are specifi c to the substance being tested, the biological specimen, and the testing device. Something else to consider is that clinical laboratories are able to set their own limits of detection. For example, the Department of Health and Human Services (DHHS) increased the cut-off values for opiates in workplace UDSs from 300 ng/mL to 2000 ng/ mL in 1998; however, some laboratories still use the more sensitive cut-off value.
3,11
Common False Positives
When health care practitioners consider performing a UDS on a patient, it is essential to obtain an accurate and detailed medication history, because many commonly used medications are known to contribute to false positive results. Table 2 summarizes the substances that have been shown to result in false positive UDS results and the illicit substance implicated as being positive.
Many drug classes, both prescription and nonprescription, have been found to contribute to false positive UDS results, including antihistamines, antidepressants, antipsychotics, antibiotics, and nonsteroidal anti-infl ammatory drugs (NSAIDs). 3, 5, 6 This further demonstrates why a thorough medication history is essential prior to screening patients. The extent of agents reported to cause false positive results demonstrates the lack of sensitivity in the initial UDS immunoassay method. This underlines the need for confi rmatory testing methods that can rule out the majority of false positive results. 2 The most common substances reported as having false positive results were amphetamines and methamphetamines. 3, 6 The majority of these false positives are caused by other stimulant substances or compounds that are structurally similar to amphetamine or methamphetamine. More than 30 substances have been reported to interfere with this immunoassay. 3, 6 This includes nonprescription, prescription, and herbal products. For example, structurally similar compounds such as brompheniramine, trazodone, and promethazine have all resulted in false positives. 6 High doses of ranitidine (ie, Ͼ150 mg/day) taken relatively close to screening (ie, Ͻ9 hours) have also been reported as false positives for amphetamine or methamphetamine on UDSs. 6, 12, 13 The fact that a wide variety of agents may lead to false positive UDS results is signifi cant. The ability of nonprescription products to interfere with the tests' validity may be particularly problematic. Patients may not recognize the importance of these medications when reporting their prescriptions; therefore, they may not discuss the use of these medications with their health care providers.
If a patient had recently developed a cough, he may not discuss his use of nonprescription cough and cold preparations because he may not recognize its relevance. However, brompheniramine, guaifenesin, and phenylephrine, which are all commonly found in nonprescription cough and cold products, have been reported as causing false positive amphetamine or methamphetamine UDSs. 6, 13 In addition, substances such as dextromethorphan, a nonprescription cough suppressant, and diphenhydramine, a nonprescription antihistamine, have been linked to false positive phencyclidine (PCP) UDSs. 6 Therefore, providers should ask patients about their use of nonprescription and herbal products prior to drug screening to get a complete medication history.
Also of note, certain NSAIDs have been reported to cause false positive UDS results. Specifi cally, naproxen, fenoprofen, and ibuprofen have been linked to cannabinoid, barbiturate, and PCP positive tests. 3, 6, 14 Oxaprozin, an NSAID indicated for rheumatic arthritis and osteoarthritis, includes a warning of the potential for false positive UDSs results in its prescribing information.
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Remember the False Negatives
Although negative results may occur due to concentrations less than the cut-off value, it is also possible that the UDS is unable to or does not routine- ■ pharmacology update ly screen for a particular substance. For example, UDSs do not effectively detect methanol, ketamine, or methylene dioxymethamphetamine (MDMA). 16 Therefore, if there is concern for 1 of these substances, alternative screening methods such as monoclonal antibodies should be used. Another potential limitation of UDSs is demonstrated by benzodiazepine screening. These tests work through the recognition of oxazepam or nordiazepam, which are common benzodiazepine metabolites; therefore, the screening tests are unable to differentiate the specifi c parent benzodiazepine. 2, 3, 16, 17 The ability to detect the specifi c parent compound may be relevant when differentiating abuse from legitimate prescription use. In addition, UDSs for opiates analyze the presence morphine, which is a metabolite of both heroin and codeine. 3 Substances such as fentanyl, which lack metabolites, and oxycodone, which is not metabolized to a morphine derivative, are typically undetected by UDS.
3,18,19
Pharmacokinetic
Considerations
Pharmacokinetic properties of the substances being screened may affect the UDS results. Absorption, distribution, metabolism, and elimination can all have a potential impact. Because the UDS detects a cutoff concentration in the urine, the rate and extent of absorption may affect the outcome. The rate of absorption varies based on the route of administration. Gastrointestinal, inhalational, or intravenous administration have variable rates of absorption, which may change the time to peak concentration and therefore the onset of action. In general, intravenous administration has the fastest rate of absorption, quickest time to peak, and quickest onset of action, which may affect detection in the UDS. The bioavailability, which can be defi ned as the extent of a substance that is present physiologically after oral ingestion, can affect the extent of absorption.
2 Substances that are less bioavailable will have decreased concentrations throughout the body, including in the urine.
Regarding distribution, lipophilic agents generally tend to have better central nervous system and tissue penetration, whereas hydrophilic substances tend to concentrate in the urine. 2 This may alter the concentration detected in a UDS and ultimately affect the results. The volume of distribution and extent of protein binding may contribute to UDS interpretation as well. Only unbound drugs are distributed and eliminated; therefore, decreased protein binding may result in shorter periods of detection through quicker elimination rates. 2 Metabolism and elimination are also important pharmacokinetic parameters to consider in the substance being screened. Screening tests may be designed to detect particular metabolites; therefore, the ability to produce specifi c metabolites, as well as the presence or absence of active metabolites, is important.
Regarding elimination, the half-life of the substance being screened is important because it directly correlates to the period of detection. The rate of elimination may be affected by the integrity of renal or hepatic function, the potential for saturation of enzyme processes and thereby the accumulation of these substances, and competition for elimination by other substances. 2 Providers should consider the saturation of these processes, which may occur at higher concentrations and result in nonlinear pharmacokinetic parameters. 2 The principle of pharmacokinetics at concentrations that result in toxicity is termed toxicokinetics. 2 These elevated concentrations can affect the normal absorption, distribution, metabolism, and elimination of substances screened in a UDS. This principle is demonstrated in that chronic, frequent, heavy users of illicit substances typically have prolonged periods of detection. In a UDS, PCP is generally detected for 4 to 7 days; however, with chronic, frequent users, periods of detection can be up to 30 days. 2 In addition to the pharmacokinetic parameters of the substance, patient-specifi c factors may contribute to the absorption, distribution, metabolism, and elimination of substances screened in UDSs. A patient's demographic characteristics such as age, weight, and sex should be considered when interpreting UDS results. 2, 20 Obese patients with increased adipose tissue may have increased distribution of lipophilic substances. 21 Patients with critical illness have altered pharmacokinetic parameters, such as renal insuffi ciency, and therefore may
THE BOTTOM LINE
• Biological specimens used to perform toxicology screens can include urine, hair, saliva, sweat and blood; however, the urine drug screen (UDS) is the most common.
• The UDS is a screening test and as such lacks sensitivity; for this reason, confi rmation of positive results by gas chromatography-mass spectrometry or high-performance liquid-chromatography is recommended.
• A variety of drug classes have been reported as the etiology of false positive urine drug screens. These classes include commonly utilized prescription and non-prescription drugs such as antihistamines, antidepressants, antipsychotics, and non-steroidal anti-infl ammatory drugs (NSAIDs).
• Providers should consider variables which may affect UDS results; which includes characteristics of the method of screening, the substance being analyzed and the patient being screened.
■ pharmacology update have inadequate fi ltering and concentrating of drug substances in the urine. 22 Changes from normal urinary pH can also affect the renal elimination of weak acids or bases due to changes in percent ionization. For example, normal urine pH is 4 to 8, but methamphetamine, which is a weak base, will have increased renal elimination with acidifi cation of the urine due to increased ionization and therefore decreased reabsorption.
2 Patientspecifi c parameters, such as these mentioned, should be considered by providers to appropriately interpret UDSs.
CONCLUSION
Toxicology screening may provide useful, objective information to clinicians to more effectively treat patients. However, the limitations of these screening methods, especially UDSs, should be recognized for appropriate analysis of results. Positive immunoassay results in the UDS should be confi rmed through a more sensitive chromatography testing method. Furthermore, it is essential to consider confounding variables such as the potential for false positives, substance specifi c pharmacokinetic parameters, and patient demographics when interpreting UDS results. There is clinical use to the UDS, but to be effectively used, it must be ordered and the results must be analyzed in the context of its limitations.
